Head-to-head evidence
CM383 vs Lecanemab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
CM383
Developed by Keymed Biosciences
NCT06412185 · Phase 1 · status unknown
This is a randomized, blinded, placebo-controlled study, but it is an early safety study in healthy volunteers rather than patients, and its primary measured outcome is safety rather than a disease outcome. Results have not yet been posted.
Next expected readout: December 2026 · NCT06619613 (registry estimate)
Lecanemab · Leqembi
Marketed by Eisai and partners
NCT01767311 · Phase 2 · completed
Randomized, triple-masked phase 2b in early Alzheimer's disease (856 participants). The Bayesian primary analysis of the ADCOMS composite at 12 months estimated a 63.8% posterior probability of meaningful benefit for the highest dose, short of the study's prespecified success criterion, so the primary endpoint was not met.
Next expected readout: December 2026 · NCT06602258 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CM383's landscape · Lecanemab's landscape